

Special Issue

Cardiac and Vascular Diseases: Pathogenesis, Pharmacological Treatments, Advances in Therapies

Message from the Guest Editors

Cardiovascular diseases are the leading cause of death worldwide. The relationship between cardiac and vascular structures is not always considered, and these diseases are often underdiagnosed. The focus of this Special Issue is to develop new insights into the pathogenesis of vascular alterations in cardiac diseases by outlining the complex genetic, biochemical, and molecular aspects at the basis of these alterations. Early identification of cardiac and vascular diseases as well as the correct evaluation of mechanisms and pathogenetic pathways will help to promote the development of targeted therapies. The landscape of cardiovascular pharmacology is the further aim of this Special Issue: authors are invited to contribute their research in the field of pharmacological approaches to cardiac and vascular diseases by outlining the most recent advances in therapies and treatments. The combination of research in pathogenesis and pharmacology will give a comprehensive overview of cardiovascular diseases and the attempts to improve the outcomes of patients suffering from them.

Guest Editors

Dr. Francesco Massari

Cardiology Department, Perinei Hospital, Bari, Italy

Prof. Dr. Pietro Scicchitano

Cardiology Department, Perinei Hospital, Bari, Italy

Deadline for manuscript submissions

closed (15 December 2021)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/82162

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).